RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: C13M21
Target: Protein tyrosine phosphatase 1B (PTP1B)
Type of nucleic acid: ssRNA
Sequence: 5'm(GA)AUUCUGUGAUCAAUUUGGCAAUCCGCCACACGAGUm(UsC)3'
Sequence length: 39
GC content: 0.4615384615384615
Affinity: Ki: 166 nM and 168 nM
Pool type: 5'-GGGAAUGGAUCCACAUCUAC‐N30-ACUGCAGACUUGACGAAGCUU-3'
Pool random region: 30
Binding buffer/conditions: HEPES (20 mM), MgCl2 (5 mM) and NaCl (125 mM) at pH 7.3 with 20 mM NaCl and 6 μM DiFMUP
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.3
Molecular weight of target: Not reported
Post-SELEX modifications: Truncated of C13 aptamer. The C13M21 aptamer was transcribed with all CTP and UTP replaced with 2′-fluorine-CTP and 2′-fluorine-UTP, respectively.
Application as quoted in the referenced paper: Therapeutic: " SELEX was used to create an RNA aptamer targeted to protein tyrosine phosphatase 1B (PTP1B), an enzyme implicated in type 2 diabetes, breast cancer and obesity. We also investigated various single-nucleotide modifications to probe their effects on the aptamer's secondary structure and inhibition properties. This family of aptamers represents an exciting option for the development of lead nucleotide-based compounds in combating several human cancers and metabolic diseases."
Additional information: C13M21 aptamer consists of part of the C13 aptamer with two additional guanine bases prior to position 21 as a result of transcription
Reference (2010, Chembiochem ): Townshend B, Aubry I, Marcellus RC, Gehring K, Tremblay ML. An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro. Chembiochem. 2010 Jul 26;11(11):1583-93. doi: 10.1002/cbic.201000208. PMID: 20572251.
Aptamer: C9
Target: Protein tyrosine phosphatase 1B (PTP1B)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAAUGGAUCCACAUCUACUGUGAUUAAUUUGGCAAUCCGCCACACUAGACUGCAGACUUGACGAAGCUU3'
Sequence length: 71
GC content: 0.4647887323943662
Affinity: Ki: 250 nM
Pool type: 5'-GGGAAUGGAUCCACAUCUAC‐N30-ACUGCAGACUUGACGAAGCUU-3'
Pool random region: 30
Binding buffer/conditions: HEPES (20 mM), MgCl2 (5 mM) and NaCl (125 mM) at pH 7.3
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.3
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " SELEX was used to create an RNA aptamer targeted to protein tyrosine phosphatase 1B (PTP1B), an enzyme implicated in type 2 diabetes, breast cancer and obesity. We also investigated various single-nucleotide modifications to probe their effects on the aptamer's secondary structure and inhibition properties. This family of aptamers represents an exciting option for the development of lead nucleotide-based compounds in combating several human cancers and metabolic diseases."
Reference (2010, Chembiochem ): Townshend B, Aubry I, Marcellus RC, Gehring K, Tremblay ML. An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro. Chembiochem. 2010 Jul 26;11(11):1583-93. doi: 10.1002/cbic.201000208. PMID: 20572251.
Aptamer: C1
Target: Sphingosylphosphorylcholine (SPC)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAAUGGAUCCACAUCUACGAAUUCUACCGUUAUUGGUGUCACCGAAGAUGUUAUUCACUGCAGACUUGACGAAGCUU3'
Sequence length: 79
GC content: 0.4430379746835443
Affinity: Kd: 20.9 ± 0.19 nM
Pool type: 5'-GGGAAUGGAUCCACAUCUACGAAUUC-N30-UUCACUGCAGACUUGACGAAGC-3′
Pool random region: 30
Binding buffer/conditions: SB: 20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 5 mM KCl
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Sphingosylphosphorylcholine (SPC) is a lysosphingolipid that exerts multiple functions, including acting as a spasmogen, as a mitogenic factor for various types of cells, and sometimes as an inflammatory mediator. This is the first case of the Systematic Evolution of Ligands by EXponential enrichment (SELEX) process being performed with a lysosphingolipid. The SPC aptamers would be valuable tools for the development of aptamer-based medical diagnosis and for elucidating the biological role of SPC."
Reference (2010, Molecules ): Horii, K., Omi, K., Yoshida, Y., Imai, Y., Sakai, N., Oka, A., Masuda, H., Furuichi, M., Tanimoto, T., & Waga, I. (2010). Development of a sphingosylphosphorylcholine detection system using RNA aptamers. Molecules (Basel, Switzerland), 15(8), 5742–5755. https://doi.org/10.3390/molecules15085742
Aptamer: C2
Target: Sphingosylphosphorylcholine (SPC)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAAUGGAUCCACAUCUACGAAUUCUUCCGUUAUUGGAGCCAAGUCGUAUCCCGAUUCACUGCAGACUUGACGAAGCUU3'
Sequence length: 80
GC content: 0.475
Affinity: Kd: 33.2 ± 0.19 nM
Pool type: 5'-GGGAAUGGAUCCACAUCUACGAAUUC-N30-UUCACUGCAGACUUGACGAAGC-3′
Pool random region: 30
Binding buffer/conditions: SB: 20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 5 mM KCl
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Sphingosylphosphorylcholine (SPC) is a lysosphingolipid that exerts multiple functions, including acting as a spasmogen, as a mitogenic factor for various types of cells, and sometimes as an inflammatory mediator. This is the first case of the Systematic Evolution of Ligands by EXponential enrichment (SELEX) process being performed with a lysosphingolipid. The SPC aptamers would be valuable tools for the development of aptamer-based medical diagnosis and for elucidating the biological role of SPC."
Reference (2010, Molecules ): Horii, K., Omi, K., Yoshida, Y., Imai, Y., Sakai, N., Oka, A., Masuda, H., Furuichi, M., Tanimoto, T., & Waga, I. (2010). Development of a sphingosylphosphorylcholine detection system using RNA aptamers. Molecules (Basel, Switzerland), 15(8), 5742–5755. https://doi.org/10.3390/molecules15085742
Aptamer: C8
Target: Sphingosylphosphorylcholine (SPC)
Type of nucleic acid: ssRNA
Sequence: 5'GGAAUGGAUCCACAUCUACGAAUUCGCAUUGUCCGCACGCAAAGCAUUAUUGUGAUUCACUGCAGACUUGACGAAGCUU3'
Sequence length: 79
GC content: 0.4556962025316455
Affinity: Kd: 90.4 ± 2.35 nM
Pool type: 5'-GGGAAUGGAUCCACAUCUACGAAUUC-N30-UUCACUGCAGACUUGACGAAGC-3′
Pool random region: 30
Binding buffer/conditions: SB: 20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 5 mM KCl
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Sphingosylphosphorylcholine (SPC) is a lysosphingolipid that exerts multiple functions, including acting as a spasmogen, as a mitogenic factor for various types of cells, and sometimes as an inflammatory mediator. This is the first case of the Systematic Evolution of Ligands by EXponential enrichment (SELEX) process being performed with a lysosphingolipid. The SPC aptamers would be valuable tools for the development of aptamer-based medical diagnosis and for elucidating the biological role of SPC."
Reference (2010, Molecules ): Horii, K., Omi, K., Yoshida, Y., Imai, Y., Sakai, N., Oka, A., Masuda, H., Furuichi, M., Tanimoto, T., & Waga, I. (2010). Development of a sphingosylphosphorylcholine detection system using RNA aptamers. Molecules (Basel, Switzerland), 15(8), 5742–5755. https://doi.org/10.3390/molecules15085742
Aptamer: m011
Target: Sphingosylphosphorylcholine (SPC)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAUCCACAUCUACGAAUUCUUCCGUUAUUGGAGCCAAGUCGUAUCCCGAUUCC3'
Sequence length: 55
GC content: 0.4909090909090909
Affinity: Kd: 221 ± 4.84 nM
Pool type: 5'-GGGAAUGGAUCCACAUCUACGAAUUC-N30-UUCACUGCAGACUUGACGAAGC-3′
Pool random region: 30
Binding buffer/conditions: SB: 20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 5 mM KCl
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Tructated aptamer derived from c1 and c2
Application as quoted in the referenced paper: Diagnostic: " Sphingosylphosphorylcholine (SPC) is a lysosphingolipid that exerts multiple functions, including acting as a spasmogen, as a mitogenic factor for various types of cells, and sometimes as an inflammatory mediator. This is the first case of the Systematic Evolution of Ligands by EXponential enrichment (SELEX) process being performed with a lysosphingolipid. The SPC aptamers would be valuable tools for the development of aptamer-based medical diagnosis and for elucidating the biological role of SPC."
Reference (2010, Molecules ): Horii, K., Omi, K., Yoshida, Y., Imai, Y., Sakai, N., Oka, A., Masuda, H., Furuichi, M., Tanimoto, T., & Waga, I. (2010). Development of a sphingosylphosphorylcholine detection system using RNA aptamers. Molecules (Basel, Switzerland), 15(8), 5742–5755. https://doi.org/10.3390/molecules15085742
Aptamer: S132B-C12
Target: Light chain of type A botulinum neurotoxin (BoNT/A) (LCA)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5′GGGAGGAGGAGAGAUGUGAACUUACAACCCGGAACAACGUCUAACAGUGUACCAUAACCCGGCAUUCAAGAAACUCUACACUGGACUGGCG3′
Sequence length: 91
GC content: 0.5054945054945055
Affinity: Kd: 111 ± 21 nM
Pool type: 5′-GGGAGGAGGAGAGATGTGAACTT-N47-AGAAACTCTACACTGGACTGGCG-3′
Pool random region: 47
Binding buffer/conditions: PBS pH 7.4, 300 mM NaCl, 3 mM MgCl2, 5 mM DTT 1 mg/ml BSA, 0.2% Tween, 1 mg/ml heparin
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 150 kDa
Application as quoted in the referenced paper: Therapeutic: " The category A agent, botulinum neurotoxin (BoNT), is the most toxic molecule known to mankind. The endopeptidase activity of light chain domain of BoNT is the cause for the inhibition of the neurotransmitter release and the flaccid paralysis that leads to lethality in botulism. These data on K(I) and IC(50) strongly suggest that the aptamers have strong potential as antidotes that can reverse the symptom caused by BoNT/A."
Additional information: 2′-fluoro-pyrimidin modified nucleic acid (2′-F-CTP and 2′-F-UTP) during in vitro transcription step to generate 2′-F-modified RNA
Reference (2010, Biochem Biophys Res Commun ): Chang, T. W., Blank, M., Janardhanan, P., Singh, B. R., Mello, C., Blind, M., & Cai, S. (2010). In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin. Biochemical and biophysical research communications, 396(4), 854–860. https://doi.org/10.1016/j.bbrc.2010.05.006
Aptamer: V7t1
Target: Receptor-binding domain (RBD) of vascular endothelial growth factor 165 (VEGF165)
Type of nucleic acid: ssDNA
Sequence: 5'TGTGGGGGTGGACGGGCCGGGTAGA3'
Sequence length: 25
GC content: 0.72
Affinity: Kd: 1.4 nM
Pool type: 5'-ATACCAGTCTATTCAATT-N30-AGATAGTATGTGCAATCA-3'
Pool random region: 30
Binding buffer/conditions: TBSE (10 mM Tris/HCl, 100 mM NaCl, and 0.05 mM EDTA; pH 7.0)
Buffer type: Other Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensors: " With the aim of creating a more effective tool for the diagnosis of cancer, we considered vascular endothelial growth factor A (VEGF-A) as a target marker protein. We also produced an aptamer heterodimer consisting of our previously derived aptamer (del5-1), which binds to the heparin-binding domain of VEGF, linked to V7t1. The resulting heterodimer bound strongly to VEGF(165) with a K(D) value of 4.7 x 10(2) pM."
Additional information: truncated version of Vap7
Reference (2010, Molecules ): Nonaka Y, Sode K, Ikebukuro K. Screening and improvement of an anti-VEGF DNA aptamer. Molecules. 2010 Jan 7;15(1):215-25. doi: 10.3390/molecules15010215. PMID: 20110884; PMCID: PMC6256979.
Aptamer: V7t1
Target: Receptor-binding domain (RBD) of vascular endothelial growth factor 121 (VEGF121)
Type of nucleic acid: ssDNA
Sequence: 5'TGTGGGGGTGGACGGGCCGGGTAGA3'
Sequence length: 25
GC content: 0.72
Affinity: Kd: 1.1 nM
Pool type: 5'-ATACCAGTCTATTCAATT-N30-AGATAGTATGTGCAATCA-3'
Pool random region: 30
Binding buffer/conditions: TBSE (10 mM Tris/HCl, 100 mM NaCl, and 0.05 mM EDTA; pH 7.0)
Buffer type: Other Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Although PSMA is one of novel biomarkers currently being investigated for the diagnosis of prostate cancer, PSMA has not been used in clinical practice yet. Thus, we focused on PSA in this study as a target protein of aptamer selection for its practical use as a molecular recognition element in biosensors."
Additional information: truncated version of Vap7
Reference (2010, Molecules ): Nonaka Y, Sode K, Ikebukuro K. Screening and improvement of an anti-VEGF DNA aptamer. Molecules. 2010 Jan 7;15(1):215-25. doi: 10.3390/molecules15010215. PMID: 20110884; PMCID: PMC6256979.
Aptamer: PSap#4-3
Target: Prostate specific antigen (PSA)
Type of nucleic acid: ssDNA
Sequence: 5′CATGCTTACCTATAGTGAACtttACTTAATGATTTCCCGGTTGTCTCtttCATGCTTACCTATAGTGAAC3′
Sequence length: 70
GC content: 0.3714285714285714
Affinity: Kd: "several tens of nM"
Pool type: 5′-CATGCTTACCTATAGTGAACttt-N24-tttCTTTGAGAACTGACTCATAC-3′
Pool random region: 24
Binding buffer/conditions: TBS buffer (10 mM Tris/HCl, 150 mM NaCl, 5 mM KCl, 5 mM MgCl2, pH 7.4)
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 33–34kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Although PSMA is one of novel biomarkers currently being investigated for the diagnosis of prostate cancer, PSMA has not been used in clinical practice yet. Thus, we focused on PSA in this study as a target protein of aptamer selection for its practical use as a molecular recognition element in biosensors."
Additional information: Post-selex screening of aptamers using genetic algorithms for improvement of affinity. An FITC-labeled single-stranded DNA library containing a 24mer randomized region linked to 20mer primer-binding sequences at both ends through 3mer thymine- (T3-) linker (5′-CATGCTTACCTATAGTGAACttt(N24)tttCTTTGAGAACTGACTCATAC-3′) was used.
Reference (2010, Biosens Bioelectron ): Savory, N., Abe, K., Sode, K., & Ikebukuro, K. (2010). Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing. Biosensors & bioelectronics, 26(4), 1386–1391. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bios.2010.07.057
Aptamer: PSap#4-6
Target: Prostate specific antigen (PSA)
Type of nucleic acid: ssDNA
Sequence: 5′CATGCTTACCTATAGTGAACtttCCGCACCGGGTACGTTTTTTGGCCtttCATGCTTACCTATAGTGAAC3′
Sequence length: 70
GC content: 0.4428571428571428
Affinity: Kd: "several tens of nM"
Pool type: 5′-CATGCTTACCTATAGTGAACttt-N24-tttCTTTGAGAACTGACTCATAC-3′
Pool random region: 24
Binding buffer/conditions: TBS buffer (10 mM Tris/HCl, 150 mM NaCl, 5 mM KCl, 5 mM MgCl2, pH 7.4)
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 33–34kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Although PSMA is one of novel biomarkers currently being investigated for the diagnosis of prostate cancer, PSMA has not been used in clinical practice yet. Thus, we focused on PSA in this study as a target protein of aptamer selection for its practical use as a molecular recognition element in biosensors."
Additional information: Post-selex screening of aptamers using genetic algorithms for improvement of affinity. An FITC-labeled single-stranded DNA library containing a 24mer randomized region linked to 20mer primer-binding sequences at both ends through 3mer thymine- (T3-) linker (5′-CATGCTTACCTATAGTGAACttt(N24)tttCTTTGAGAACTGACTCATAC-3′) was used.
Reference (2010, Biosens Bioelectron ): Savory, N., Abe, K., Sode, K., & Ikebukuro, K. (2010). Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing. Biosensors & bioelectronics, 26(4), 1386–1391. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bios.2010.07.057
Aptamer: PSap#4-9
Target: Prostate specific antigen (PSA)
Type of nucleic acid: ssDNA
Sequence: 5′CATGCTTACCTATAGTGAACtttAATATCAACTTGCCATCAAATATCtttCATGCTTACCTATAGTGAAC3′
Sequence length: 70
GC content: 0.3285714285714285
Affinity: Kd: "several tens of nM"
Pool type: 5′-CATGCTTACCTATAGTGAACttt-N24-tttCTTTGAGAACTGACTCATAC-3′
Pool random region: 24
Binding buffer/conditions: TBS buffer (10 mM Tris/HCl, 150 mM NaCl, 5 mM KCl, 5 mM MgCl2, pH 7.4)
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 33–34kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Although PSMA is one of novel biomarkers currently being investigated for the diagnosis of prostate cancer, PSMA has not been used in clinical practice yet. Thus, we focused on PSA in this study as a target protein of aptamer selection for its practical use as a molecular recognition element in biosensors."
Additional information: Post-selex screening of aptamers using genetic algorithms for improvement of affinity. An FITC-labeled single-stranded DNA library containing a 24mer randomized region linked to 20mer primer-binding sequences at both ends through 3mer thymine- (T3-) linker (5′-CATGCTTACCTATAGTGAACttt(N24)tttCTTTGAGAACTGACTCATAC-3′) was used.
Reference (2010, Biosens Bioelectron ): Savory, N., Abe, K., Sode, K., & Ikebukuro, K. (2010). Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing. Biosensors & bioelectronics, 26(4), 1386–1391. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bios.2010.07.057
Aptamer: PSap#4-11
Target: Prostate specific antigen (PSA)
Type of nucleic acid: ssDNA
Sequence: 5′CATGCTTACCTATAGTGAACtttGTGTTGCCCGGAACGTCGTGGCCCtttCATGCTTACCTATAGTGAAC3′
Sequence length: 70
GC content: 0.4714285714285714
Affinity: Kd: "several tens of nM"
Pool type: 5′-CATGCTTACCTATAGTGAACttt-N24-tttCTTTGAGAACTGACTCATAC-3′
Pool random region: 24
Binding buffer/conditions: TBS buffer (10 mM Tris/HCl, 150 mM NaCl, 5 mM KCl, 5 mM MgCl2, pH 7.4)
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 33–34kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Although PSMA is one of novel biomarkers currently being investigated for the diagnosis of prostate cancer, PSMA has not been used in clinical practice yet. Thus, we focused on PSA in this study as a target protein of aptamer selection for its practical use as a molecular recognition element in biosensors."
Additional information: Post-selex screening of aptamers using genetic algorithms for improvement of affinity. An FITC-labeled single-stranded DNA library containing a 24mer randomized region linked to 20mer primer-binding sequences at both ends through 3mer thymine- (T3-) linker (5′-CATGCTTACCTATAGTGAACttt(N24)tttCTTTGAGAACTGACTCATAC-3′) was used.
Reference (2010, Biosens Bioelectron ): Savory, N., Abe, K., Sode, K., & Ikebukuro, K. (2010). Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing. Biosensors & bioelectronics, 26(4), 1386–1391. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bios.2010.07.057
Aptamer: 21-E
Target: Zinc-finger antiviral protein (ZAP)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAACAGUCCGAGCCUGCGUGCGAGGAGGUGGAGAGGGUGGGUGUGCGUGGCGUGGGGUGAAUUCGUCAUA3'
Sequence length: 72
GC content: 0.6388888888888888
Affinity: Not reported
Pool type: 5'-GGGAACAGUCCGAGCC-N40-GGGUGAAUUCGUCAUA-3'
Pool random region: 40
Binding buffer/conditions: 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, and 10 μM ZnCl2
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " TThe zinc-finger antiviral protein (ZAP) is a host factor that specifically inhibits the replication of certain viruses, including murine leukemia virus, Sindbis virus and Ebola virus, by targeting the viral mRNAs for degradation. The aptamers identified in this report should provide useful tools to further investigate the details of the interaction between ZAP and the target RNAs."
Reference (2010, Protein Cell ): Huang Z, Wang X, Gao G. Analyses of SELEX-derived ZAP-binding RNA aptamers suggest that the binding specificity is determined by both structure and sequence of the RNA. Protein Cell. 2010 Aug;1(8):752-9. doi: 10.1007/s13238-010-0096-9. Epub 2010 Aug 28. PMID: 21203916; PMCID: PMC4875198.
Aptamer: 21-K
Target: Zinc-finger antiviral protein (ZAP)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAACAGUCCGAGCCAAGCGGUAGCGUCAGGGGGUGGAGGGAGGAGGCCGCGUGGUGUGGGUGAAUUCGUCAUA3'
Sequence length: 75
GC content: 0.64
Affinity: Not reported
Pool type: 5'-GGGAACAGUCCGAGCC-N40-GGGUGAAUUCGUCAUA-3'
Pool random region: 40
Binding buffer/conditions: 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, and 10 μM ZnCl2
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " TThe zinc-finger antiviral protein (ZAP) is a host factor that specifically inhibits the replication of certain viruses, including murine leukemia virus, Sindbis virus and Ebola virus, by targeting the viral mRNAs for degradation. The aptamers identified in this report should provide useful tools to further investigate the details of the interaction between ZAP and the target RNAs."
Reference (2010, Protein Cell ): Huang Z, Wang X, Gao G. Analyses of SELEX-derived ZAP-binding RNA aptamers suggest that the binding specificity is determined by both structure and sequence of the RNA. Protein Cell. 2010 Aug;1(8):752-9. doi: 10.1007/s13238-010-0096-9. Epub 2010 Aug 28. PMID: 21203916; PMCID: PMC4875198.
Aptamer: FB4
Target: Mouse transferrin receptor (TfR-ECD)
Type of nucleic acid: ssRNA
Sequence: 5'GGGCGAAUUCCGCGUGUGCUGAGGGCGGAAGAACUAAUUUGGGACGGAUUGCGGCCGUUGUCUGUGGCGUCCGUUCGGG3'
Sequence length: 79
GC content: 0.620253164556962
Affinity: Not reported
Pool type: 5'-TAATACGACTCACTATAGGGCGAATTCCGCGTGTGC-49N-GTCCGTTCGGGATCCTC-3'
Pool random region: 49
Binding buffer/conditions: DNA binding buffer PBS containing 1 mM MgCl2 (PBSM)
Divalent salt: MgCl 
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Research:". In this study, we chose an RNA and a DNA aptamer binding to the extracellular domain of mouse TfR (TfR-ECD) and demonstrated their ability to deliver streptavi_x0002_din to Ltk_x0002_ cells. We then showed the ability of the DNA aptamer to deliver a lysosomal enzyme into deficient mouse fibroblasts and correct the defective glycosaminoglycan (GAG) degradation in these cells
Additional information: After characterization in the model system, the DNA aptamer was conjugated to a lysosomal enzyme, α-l-iduronidase, from which mannose 6-phosphate had been removed. The aptamer had been modified by attachment of terminal glycerol for oxidation by periodate and reaction of the resulting aldehyde with amino groups on the protein.
Reference (2008,Proc Natl Acad Sci U S A): Chen, C. H., Dellamaggiore, K. R., Ouellette, C. P., Sedano, C. D., Lizadjohry, M., Chernis, G. A., Gonzales, M., Baltasar, F. E., Fan, A. L., Myerowitz, R., & Neufeld, E. F. (2008). Aptamer-based endocytosis of a lysosomal enzyme. Proceedings of the National Academy of Sciences of the United States of America, 105(41), 15908–15913. https://doi.org/10.1073/pnas.0808360105